Literature DB >> 8111044

Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura.

R He1, D M Reid, C E Jones, N R Shulman.   

Abstract

The characteristic decreased recovery and survival of transfused platelets in nonalloimmunized patients with idiopathic thrombocytopenic purpura (ITP) suggest that plasma antiplatelet autoantibodies (autoAbs) are present in almost all cases. Studies emphasizing reactions of IgG autoAbs with platelet glycoprotein (GP) IIb/IIIa indicate that less than 50% of ITP patients have detectable serum Abs, and that many of these Abs may not be pathogenic because they are directed against epitopes in the cytoplasmic domain of GPIIIa (Fujisawa et al, Blood 77:2207, 1991 and 79:1441, 1992). We evaluated the contribution of Ig classes other than IgG to the overall incidence of serum Abs in 47 patients with chronic ITP and the frequency of reactions with GPs IIb/IIIa, Ib/IX, IV, and Ia/IIa. Abs were further characterized by their reactions with cytosolic or exosolic GP epitopes and their titers and apparent affinities. Using immunobead techniques we found (1) anti-GPs in 85% of sera; (2) IgA and IgG Abs each in 68%, together in 51%; (3) IgM agglutinins in 15%, always with another Ab class; (4) GP Ib/IX, IIb/IIIa, IV, and Ia/IIa targets in 83%, 81%, 38%, and 28% of cases, respectively; (5) 93% of positive sera reactive with more than one GP; but GP IV or Ia/IIa never the sole target; (6) Abs against cytosolic epitopes on one or more of GPs IIIa, Ib alpha, and IIb beta in 66% of sera, always accompanied by Abs against exosolic epitopes of the same or a different GP; (7) autoAbs against cytosolic GP epitopes in 38% of 16 patients recovered from posttransfusion purpura and drug purpura; and (8) evidence that serum ITP Abs, often high-titered, saturate platelets less than alloAbs against the same GPs. Whereas Abs against external GP epitopes are a distinctive marker for ITP in 80% of patients, Abs against internal GP epitopes are likely a secondary phenomenon of platelet destruction and not pathogenic. Anti-GPs against exosolic epitopes were also found in eluates of patient's platelets, suggesting that they have pathogenic significance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8111044

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Are maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage?

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

2.  Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia.

Authors:  S Audia; K Santegoets; A G Laarhoven; G Vidarsson; O Facy; P Ortega-Deballon; M Samson; N Janikashvili; P Saas; B Bonnotte; T R Radstake
Journal:  Clin Exp Immunol       Date:  2017-02-28       Impact factor: 4.330

3.  The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies.

Authors:  Conglei Li; Siavash Piran; Pingguo Chen; Sean Lang; Alessandro Zarpellon; Joseph W Jin; Guangheng Zhu; Adili Reheman; Dianne E van der Wal; Elisa K Simpson; Ran Ni; Peter L Gross; Jerry Ware; Zaverio M Ruggeri; John Freedman; Heyu Ni
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

4.  Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia.

Authors:  Etienne Crickx; Pascal Chappert; Aurélien Sokal; Sandra Weller; Imane Azzaoui; Alexis Vandenberghe; Guillaume Bonnard; Geoffrey Rossi; Tatiana Fadeev; Sébastien Storck; Jehane Fadlallah; Véronique Meignin; Etienne Rivière; Sylvain Audia; Bertrand Godeau; Marc Michel; Jean-Claude Weill; Claude-Agnès Reynaud; Matthieu Mahévas
Journal:  Sci Transl Med       Date:  2021-04-14       Impact factor: 17.956

5.  Antiplatelet glycoprotein autoantibodies in patients with autoimmune diseases with and without thrombocytopenia.

Authors:  I Cordiano; F Salvan; M L Randi; M A Ruffatti; A Steffan; A Girolami; F Fabris
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

6.  Laboratory investigation of immune thrombocytopenia.

Authors:  M Warner; J G Kelton
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

7.  Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia.

Authors:  Sabrina Shrestha; Ishac Nazy; James W Smith; John G Kelton; Donald M Arnold
Journal:  Blood Adv       Date:  2020-07-14

8.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

9.  Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle.

Authors:  Andreas Rank; Oliver Weigert; Helmut Ostermann
Journal:  Biologics       Date:  2010-05-25

10.  Complications of Evans' syndrome in an infant with hereditary spherocytosis: a case report.

Authors:  Hideki Yoshida; Hiroyuki Ishida; Takao Yoshihara; Takashi Oyamada; Masataka Kuwana; Toshihiko Imamura; Akira Morimoto
Journal:  J Hematol Oncol       Date:  2009-09-10       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.